SEC Form 4 · accession 0001193125-26-352206
Pyxis Oncology, Inc. · PYXS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Civik
Officer — Interim CEO · Director
Period of report
Aug 12, 2026
Accepted (ET)
Aug 14, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001782223
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.49 | Aug 12, 2026 | A | 250,956 | A | Aug 12, 2026 | Feb 3, 2036 | Common Stock | 250,956 | 941,087 | D |
Explanation of responses
- F1Represents the performance-based portion of an option that was granted on February 3, 2026, which shares subject to this portion of the option were to become vested in full upon the completion of a successful financing transaction or a successful strategic transaction during the reporting person's continued service as Interim Chief Executive Officer or within six months thereafter. The performance conditions were deemed to have been met on August 12, 2026, as determined by the Board.